-
Strategies for a discontinuous future.





Consulting & advisory, research notes, in the press, about bubblegen,
next wednesdays.





Monday, November 17, 2003
 


[email protected] has a kind of interesting if kind of random article about biotech and the dynamics of innovation. It doesn't really make much of an argument either way, apart from noting that the pharma industry is in a bit of trouble, and that biotech is the light at the end of the tunnel.

So what else is new? The real problem is that very few people investing in biotech actually understand how radically different a game it is than tech.

-- umair // 6:45 PM //


Comments:
Post a Comment
search




Public

Recent & upcoming sessions:

Supernova 2007 (video)

NMKForum



new




input

due diligence
ventureblog
a vc
techblurbs
tj's weblog
venture chronicles
terranova
the big picture
gigaom
venchar
bill burnham
babak nivi
n-c thoughts
paidcontent
techdirt
slashdot
london gsb
mefi
boingboing
blort
hardwax
betalounge

ing
morgan
chicago fed
dallas fed
ny fed
imf
world bank
nouriel roubini

portfolio
contact

mail.
uhaque (dot) mba2003 (at) london (dot) edu

skype.
umair.haque

atom feed

technorati profile

blog archives